UbcH6 (UBE2E1) Active Human Recombinant Protein
- Known as:
- UbcH6 (UBE2E1) Active Human Recombinant Protein
- Catalog number:
- 80316
- Product Quantity:
- 100 µg
- Category:
- -
- Supplier:
- BPS Bioscience
- Gene target:
- UbcH6 (UBE2E1) Active Human Recombinant Protein
Related genes to: UbcH6 (UBE2E1) Active Human Recombinant Protein
- Gene:
- UBE2E1 NIH gene
- Name:
- ubiquitin conjugating enzyme E2 E1
- Previous symbol:
- -
- Synonyms:
- UbcH6
- Chromosome:
- 3p24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-03-21
- Date modifiied:
- 2016-03-14
Related products to: UbcH6 (UBE2E1) Active Human Recombinant Protein
Related articles to: UbcH6 (UBE2E1) Active Human Recombinant Protein
- BACKGROUND: Saxagliptin is a DPP-4 inhibitor widely used to manage type 2 diabetes, though genetic contributors to variability in response remain unclear. This study aimed to identify genetic variants associated with the efficacy and safety of saxagliptin using genome-wide association studies (GWAS) with data from randomized controlled trials. METHODS: GWAS were conducted on glycated hemoglobin (HbA1c) levels and hypoglycemic events in saxagliptin-treated individuals from 12 phase II or III clinical trials. Additional exploratory traits included fasting glucose, weight, body mass index, systolic and diastolic blood pressure, heartbeat, and renal function. Primary analyses focused on participants of European ancestry, followed by analyses in the overall multi-ancestry cohort. Linear mixed models for continuous traits and Cox proportional hazards models for time-to-event analyses were used, including gene-by-sex and gene-by-treatment interactions. We also performed a transcriptome-wide association study (TWAS) to identify genes whose predicted expression is associated with the response to saxagliptin using the S-PrediXcan framework. RESULTS: Among 1 016 European and 1 826 multi-ancestry saxagliptin-treated participants, no genome-wide significant associations were observed. Suggestive associations included rs2168426:T > C near UBE2E1 for HbA1c (p = 1.0 × 10⁻⁷) and rs138558907:C > T near CCSER2 for hypoglycemia (p = 6.1 × 10⁻⁸). Treatment interaction analyses showed a stronger rs2168426 effect on HbA1c among saxagliptin users compared with non-users (pint = 9.2 × 10⁻³). The TWAS revealed three genes that significantly associated with HbA1c in human tissues: OGFOD3 in aorta (p = 8.3 × 10⁻⁷), TBC1D3D in coronary artery (p = 3.3 × 10⁻⁶), and TYSND1 in amygdala (p = 3.9 × 10⁻⁶). In the multi-ancestry cohort, KDM7A in whole blood was significantly associated with HbA1c (p = 3.6 × 10⁻⁶). CONCLUSION: Larger, diverse studies are needed to identify pharmacogenomic determinants of responses to saxagliptin. - Source: PubMed
Publication date: 2026/03/26
Pilon Marc-Olivierde Denus SimonAsselin GéraldineLegault Marc-AndréNgongang Kwandjang Hervira BrendaBarhdadi AminaLemieux Perreault Louis-PhilippeValois DianeMongrain IanHaefliger CarolinaPaul Dirk SPearson Ewan RTardif Jean-ClaudeDubé Marie-Pierre - Senile osteoporosis (SOP) is linked to the ubiquitination process, with dysregulation of ubiquitin-mediated protein turnover disrupting bone remodeling and resulting in decreased bone mineral density (BMD). This study aimed to identify biomarkers related to ubiquitination in SOP and explore their molecular regulatory mechanisms. - Source: PubMed
Publication date: 2025/12/12
Cheng XiyueLiu JunchuanGuan YimanJing BoyaZhao JingCao Yan - Glioblastoma multiforme (GBM), the most prevalent and lethal type of brain cancer, is characterized by a poor prognosis despite advancements in comprehensive treatments, including surgery, chemotherapy, and radiotherapy. Lactylation, an emerging epigenetic modification, has been shown to influence the biological behavior of tumor cells; however, its role in GBM remains to be further elucidated. - Source: PubMed
Publication date: 2025/08/07
Xiao YifeiZheng RuipengLv FengjunYang GuangGe HaitaoYang MingchunWang KanCheng Yu - Programmed cell death (PCD) mechanisms play crucial roles in cancer progression and treatment response. This study aims to develop a PCD scores prediction model to evaluate the prognosis of hepatocellular carcinoma (HCC) and elucidate the tumor microenvironment differences. - Source: PubMed
Publication date: 2025/07/16
Lei KaiZhao YutongLi ShuminLiu JiaweiChen WenhaoZhou CaihongZhang YiTan JinmeiWu JianZhou QiTan Jiehui - Moyamoya disease (MMD) is a chronic, progressive occlusive cerebrovascular disease. It causes recurrent cerebrovascular stroke due to vascular closure and proliferation. An unclear pathophysiological mechanism is the most significant obstacle in the diagnosis and treatment of MMD. - Source: PubMed
Publication date: 2025/07/28
Zhou ZhenyuNiu HongchuanXu ShaoqiZhang JunzeLiu YutongLei ChengxuHe ShihaoZhao Yuanli